Medical Device | September 24, 2025
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Shantived Hospital generated revenue of around Rs 50 crore in FY2025
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
The company has received approval from DCGI to begin patient enrolment and dosing in the country
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Subscribe To Our Newsletter & Stay Updated
